Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

• ClinicalTrials.gov Identifier: NCT03637543
• Recruitment Status: Recruiting
• First Posted: August 20, 2018
• Last Update Posted: December 7, 2022
• Sponsor: Beth Israel Deaconess Medical Center
• Collaborator: Bristol-Myers Squibb
• Information provided by (Responsible Party): David J. Einstein, MD, Beth Israel Deaconess Medical Center

Study Description

Brief Summary:

This research study is studying an immune-based cancer drug as a possible treatment for prostate cancer.

The drug involved in this study is:

-Nivolumab

Condition or disease	Intervention/treatment	Phase
Prostate Cancer	Drug: Nivolumab	Phase 2

Detailed Description:

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved nivolumab for this specific disease but it has been approved for other uses. Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer.

In this research study, the investigators are investigating whether nivolumab has any activity in patients who have a rising PSA (prostate specific antigen) after previously undergoing surgery or radiation for prostate cancer. Although nivolumab was previously not found to have significant effect in advanced prostate cancer after all other therapies had failed, based on new research, the investigators are testing whether nivolumab could have a greater effect earlier in the disease course and before patients receive hormone therapies.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 34 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2 Study of Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
• Actual Study Start Date: October 18, 2018
• Estimated Primary Completion Date: March 31, 2023
• Estimated Study Completion Date: March 31, 2025

Arms and Interventions

Arm	Intervention/treatment
Experimental: PD-L1 Positive; -Nivolumab will be given on day 1 of a 28-day cycle intravenously	Drug: Nivolumab; Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer; Other Name: Opdivo
Experimental: PD-L1 Negative; -Nivolumab will be given on day 1 of a 28-day cycle intravenously	Drug: Nivolumab; Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer; Other Name: Opdivo

Outcome Measures

Primary Outcome Measures :

1. Disease Control [ Time Frame: 12 weeks ]
   Proportion of patients with high-risk biochemically-recurrent (BCR) prostate cancer (PCa) that experiences decline or stabilization in PSA (without symptomatic/radiographic progression) after 12 weeks of nivolumab treatment

Secondary Outcome Measures :

1. Maximal change in prostate specific antigen (PSA) during nivolumab treatment [ Time Frame: 2 years ]
2. Best PSA response during nivolumab treatment as an absolute change relative to baseline [ Time Frame: 2 years ]
3. Change in PSA doubling time (PSADT) at end-of-study relative to baseline [ Time Frame: 2 years ]
4. Time from enrollment to development of radiographic metastatic disease [ Time Frame: 2 years ]
5. Time from enrollment to initiation of androgen deprivation therapy (ADT) [ Time Frame: 2 years ]
6. Treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: 2 years ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients must have signed an informed-consent form indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study.
• Patients must have a history of prostate adenocarcinoma (adenocarcinoma must be the primary histology; secondary components of variant histologies are acceptable) confirmed on biopsy and treated with primary radical prostatectomy (RP) or definitive radiation (RT). Prior salvage RT is acceptable.

• Patients must have experienced biochemical recurrence (BCR) plus have minimum PSA values noted below:

  • Following primary RP: Any detectable rising PSA after RP (or after salvage RT if performed), minimum PSA 1.0 at time of screening
  • Following primary RT: PSA rise to ≥2 ng/mL above the nadir
  • No evidence of metastases on conventional imaging (CT or MRI plus bone scan)
• PSA doubling time (PSADT) <10 months --PSADT: calculated as per Prostate Cancer Working Group 3 (PCWG3) and the Memorial Sloan Kettering Cancer Center calculator: (https://www.mskcc.org/nomograms/prostate/psa_doubling_time)

With linear regression model of normal logarithm of PSA and time, based on:

• At least 3 consecutive PSA values with each value ≥0.2 ng/mL

• Interval between first and last PSA values is ≥8 weeks but ≤12 months.

  -Archival tissue is mandatory, either prostatectomy specimen or (in patients who received primary RT) diagnostic core biopsies. Patients must consent to next-generation sequencing performed on this tissue.

• If diagnostic core biopsies are only available tissue, at least 3 cores must be involved by tumor

  • Easteron Cooperative Oncology Group (ECOG) performance status 0-1
  • Age ≥18 years
  • Adequate organ and marrow function:
  • System Laboratory Value
• Hematological
• White blood cell (WBC) ≥ 2000/µL
• Absolute Neutrophil Count (ANC) ≥ 1500/μL
• Platelets (Plt) ≥ 100 x103/μL

• Hemoglobin (Hgb) > 9.0 g/dL (with or without transfusion)

  -Renal

• Serum Creatinine ≤ 2 x ULN
• Hepatic
• Bilirubin1 ≤ 1.5× upper limit of normal (ULN)
• Aspartate aminotransferase (AST) ≤ 3 × ULN

• Alanine aminotransferase (ALT) ≤ 3 × ULN

  • Except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL
  • Baseline testosterone ≥100 ng/dL
  • Recovery from acute toxicity related to prior therapy, including surgery and radiation, or no treatment-related toxicity ≥ grade 2.
  • History of prior malignancy or concurrent separate malignancy is not an exclusion criterion so long as the non-prostate malignancy is stable and does not require any treatment.
  • Able to understand and sign informed consent and adhere to study procedures.
  • Male patients whose female partners are of reproductive potential must agree to use a contraception during the trial period

Exclusion Criteria:

• Current use of ADT or plan to initiate ADT during trial period
• Major surgery or radiation therapy within 14 days of starting study treatment
• Subjects with active autoimmune disease. Patients with a history of autoimmune disease that has not required systemic immunosuppressive therapy or does not threaten vital organ function including central nervous system, heart, lungs, kidneys, skin, and gastrointestinal tract will be allowed.
• Known history of immune deficiencies or chronic viral infections including HIV, hepatitis B (HBV), and hepatitis C (HCV) (patients with prior therapy for HBV or HCV is permitted if viral clearance was documented).
• Concurrent medical condition requiring use of systemic corticosteroids with prednisone >10 mg per day or equivalent. Use of inhaled, nasal, and topical steroids (applied to small body areas) is allowed.
• Current use (within past 4 weeks) of other prohibited medications including anti-cancer therapies, hormonal therapies, 5-alpha reductase inhibitors, and alternative medications known to alter PSA (e.g. phytoestrogens and saw palmetto).
• Prior treatment with immune checkpoint inhibitors. (Prior cancer vaccines are allowed.)
• Serious intercurrent medical or psychiatric illness that, in the judgment of the investigator, would interfere with patient's ability to carry out the treatment program

Contacts and Locations

Contacts

Contact: David J. Einstein, MD; 617-667-2100; deinstei@bidmc.harvard.edu

Locations

United States, Massachusetts

St. Elizabeth's Medical Center; Recruiting

Boston, Massachusetts, United States, 02135

Contact: Olga Kozyreva, MD Olga_Kozyreva@DFCI.HARVARD.EDU

Beth Israel Deaconess Medical Center; Recruiting

Boston, Massachusetts, United States, 02215

Contact: David J. Einstein, MD 617-667-2100 deinstei@bidmc.harvard.edu

Principal Investigator: David J. Einstein, MD

Dana Farber Cancer Institute; Recruiting

Boston, Massachusetts, United States, 02215

Contact: Xiao Wei, MD XiaoX_Wei@DFCI.HARVARD.EDU

Principal Investigator: Xiao Wei, MD

DFCI South Shore; Recruiting

South Weymouth, Massachusetts, United States, 02190

Contact: Thomams O'Connor, MD thomasp_o'connor@dfci.harvard.edu

United States, New Hampshire

DFCI Londonderry; Recruiting

Londonderry, New Hampshire, United States, 03053

Contact: Frederick Briccetti, MD fred_briccetti@dfci.harvard.edu

Sponsors and Collaborators

Beth Israel Deaconess Medical Center

Bristol-Myers Squibb

Investigators

• Principal Investigator: David J. Einstein, MD; Beth Israel Deaconess Medical Center

More Information

• Responsible Party: David J. Einstein, MD, Principal Investigator, Beth Israel Deaconess Medical Center
• ClinicalTrials.gov Identifier: NCT03637543
• Other Study ID Numbers: 18-249
• First Posted: August 20, 2018
• Last Update Posted: December 7, 2022
• Last Verified: December 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by David J. Einstein, MD, Beth Israel Deaconess Medical Center:

Prostate Cancer

Additional relevant MeSH terms:

Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Prostatic Diseases; Nivolumab; Antineoplastic Agents, Immunological; Antineoplastic Agents; Immune Checkpoint Inhibitors; Molecular Mechanisms of Pharmacological Action